<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02982057</url>
  </required_header>
  <id_info>
    <org_study_id>Non Culprit Lesion Study</org_study_id>
    <nct_id>NCT02982057</nct_id>
  </id_info>
  <brief_title>Non Culprit Lesion Study</brief_title>
  <official_title>A Randomized Trial of the Treatment of Non- Culprit Lesion After STEMI: Bioresorbable Vascular Scaffold Versus Optimal Medical Therapy (NCLstudy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare the evolution of non culprit lesions after
      treatment by BVS versus optimal medical therapy at 2-years follow- up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives and hypothesis: scaffolding a non culprit /vulnerable coronary plaque with BVS
      could facilitate the stabilization process into the atherosclerotic plaque with modifications
      of plaque morphology, especially the lipid content which is considered as one of the main
      factor leading to recurrent MACE after an ACS.

      The interaction between the polymer Platform and the vessel wall, the effect of the
      everolimus on neointima growth and cellular response into the media could reduce the
      inflammatory process into the vulnerable plaque could be different Under OMT and BVS
      implantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure size of the vulnerable plaque</measure>
    <time_frame>2 years</time_frame>
    <description>the size of the vulnerable plaque measured by angio FU at 2 years with an investigation of the same segment than at baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Bioresorbable vascular scaffold(BVS)+ OMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.
Intervention:Device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OMT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.
Intervention: medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>the ABSORB:bioresorbable vascular scaffold</intervention_name>
    <arm_group_label>Bioresorbable vascular scaffold(BVS)+ OMT</arm_group_label>
    <other_name>to compare to optimal medical treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O.M.T</intervention_name>
    <arm_group_label>OMT</arm_group_label>
    <other_name>to compare with device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI and multivessel ASCL

          -  Successful and uneventful primary PCI

          -  Non culprit lesion &gt; /= 2.5mm RVD suitable for investigation by FFR

          -  At least one segment of minimum 10 mm length containing a non culprit lesion

        Exclusion Criteria:

          -  non compliant profile

          -  patient not able to sign an IC

          -  cardiogenic shock

          -  left main disease

          -  GFR&lt;30ml/min/m2

          -  previous CABG

          -  LVEF&lt;35%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>StLuc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joelle Kefer, investigator</last_name>
      <phone>003227642889</phone>
      <phone_ext>42889</phone_ext>
      <email>joelle.kefer@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Anne Bouvier, study coordinator</last_name>
      <phone>003227642966</phone>
      <phone_ext>42966</phone_ext>
      <email>anne.bouvier@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

